Iberdomide, Daratumumab, and Dexamethasone vs. Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory MM

A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM)(Excaliber-RRMM)(CC-220-MM-002)

Disease Types: Myelomas

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM)(Excaliber-RRMM)(CC-220-MM-002)

For More Information:

https://clinicaltrials.gov/study/NCT04975997?term=Excaliber-RRMM&rank=1